Nature Reviews Clinical Oncology - Table of Contents alert Volume 12 Issue 9

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
September 2015 Volume 12 Number 9
Impact Factor 14.180 *	In this issue Editorial Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Refining the treatment of NSCLC according to histological and molecular subtypes Anish Thomas, Stephen V. Liu, Deepa S. Subramaniam & Giuseppe Giaccone
Subscribe   Facebook   RSS   Recommend to library   Twitter
EDITORIAL		Top
Oncology drug pricing structure is broken Lisa Hutchinson Published online: 26 August 2015 p499 | doi:10.1038/nrclinonc.2015.141 Full Text | PDF
RESEARCH HIGHLIGHTS Top Breast cancer: Rational use of regional nodal irradiation needed Published online: 04 August 2015 p501 | doi:10.1038/nrclinonc.2015.136 PDF CNS cancer: Molecular classification of glioma Published online: 14 July 2015 p502 | doi:10.1038/nrclinonc.2015.111 PDF Urological cancer: Management of patients with prostate cancer: evolution towards a risk-stratified approach Published online: 28 July 2015 p503 | doi:10.1038/nrclinonc.2015.135 PDF Imaging: Improving detection of bone metastases in renal cell carcinoma Published online: 11 August 2015 p503 | doi:10.1038/nrclinonc.2015.138 PDF Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer Published online: 30 June 2015 p504 | doi:10.1038/nrclinonc.2015.122 PDF Radiotherapy: Abscopal responses: pro-immunogenic effects of radiotherapy Published online: 14 July 2015 p504 | doi:10.1038/nrclinonc.2015.127 PDF Haematological cancer: Promising results of BCL2 inhibition Published online: 11 August 2015 p504 | doi:10.1038/nrclinonc.2015.139 PDF IN BRIEF Melanoma: Dabrafenib and trametinib improve overall survival | Haematalogical cancer: Elotuzumab reduces risk of multiple myeloma progression | Genetics: Whole-exome sequencing yields clinically useful information | Gynaecological cancer: Less than three doses of HPV-16/18 prevents HPV infection PDF Clinical Oncology JOBS of the week Research Fellow - Molecular Medicine / Oncology Mayo Clinic Postdoctoral Scientist Helmholtz Association Sr Scientist - Head of Experimental Therapeutics Dana-Farber Cancer Institute (DFCI) Postdoc Netherlands Cancer Institute Postdoctoral position at the Institute of Cellular and Molecular Radiation Biology INSERM/CEA More Science jobs from Clinical Oncology EVENT 2015 Scientific Conference - Pediatric Oncology 09.11.15 Fort Lauderdale, USA More science events from
NEWS AND VIEWS		Top
Breast cancer: Oophorectomy for BRCA1 ER-negative disease—an open debate Noah Kauff & Mark Robson Published online: 21 July 2015 p505 | doi:10.1038/nrclinonc.2015.130 Risk-reducing salpingo-oophorectomy (RRSO) is a standard intervention in BRCA1 or BRCA2 mutation carriers owing to its associated reduction in mortality related to ovarian and breast cancer. A study has now reported a beneficial impact of adjuvant RRSO in patients with BRCA1 mutations and breast cancer. However, various biases confound these results. Full Text | PDF
Clinical trials: Subgroup analyses in randomized trials—more rigour needed Douglas G. Altman Published online: 28 July 2015 p506 | doi:10.1038/nrclinonc.2015.133 An analysis of reports from phase III trials (published between 2011 and 2013) investigating patients with solid tumours found widespread failings in both the conduct and reporting of subgroup analyses. Readers might well be misled by such analyses. Editors should, therefore, implement policies to reduce the risk of publishing misleading results. Full Text | PDF
Breast cancer: Weekly paclitaxel—still preferred first-line taxane for mBC Joseph Gligorov & Sandrine Richard Published online: 11 August 2015 p508 | doi:10.1038/nrclinonc.2015.137 Taxane-based regimens are among the preferred first-line chemotherapy options for metastatic breast cancer, with weekly paclitaxel considered equivalent to 3-weekly docetaxel. The CALGB 40502/NCCTG N063H (Alliance) trial has now compared bevacizumab plus weekly paclitaxel, nab-paclitaxel, or ixabepilone in this setting; ixabepilone was inferior and nab-paclitaxel was not superior, with a trend towards inferiority. Paclitaxel thus remains the standard-of-care taxane chemotherapy. Full Text | PDF
REVIEWS		Top
Refining the treatment of NSCLC according to histological and molecular subtypes Anish Thomas, Stephen V. Liu, Deepa S. Subramaniam & Giuseppe Giaccone Published online: 12 May 2015 p511 | doi:10.1038/nrclinonc.2015.90 The recognition of non-small-cell lung cancer (NSCLC) as a heterogeneous disease and ongoing efforts to characterize disease subtypes based on genotype and histology have resulted in dramatic improvements in outcomes for select patient subgroups. However, many challenges remain, not least acquired therapeutic resistance and the related issue of how to best use the available therapies. In this Review, the authors provide an overview of the key developments in NSCLC therapy, describe efforts to tackle therapeutic resistance, and discuss potential strategies to further optimize patient outcomes by stratifying treatments according to particular disease subtypes. Abstract | Full Text | PDF
Opportunities and challenges of radiotherapy for treating cancer Dörthe Schaue & William H. McBride Published online: 30 June 2015 p527 | doi:10.1038/nrclinonc.2015.120 Although dramatic changes in the delivery of radiation therapy have occurred, the impact of radiobiology on the clinic has been far less substantial. New advances are uncovering some of the mechanistic processes that underlie the differences between the tumour and host tissue characteristics. The authors of this Review focus on how these processes might be targeted to improve the outcome of radiotherapy for patients. Abstract | Full Text | PDF
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer Christopher D. Hart, Ilenia Migliaccio, Luca Malorni, Cristina Guarducci, Laura Biganzoli & Angelo Di Leo Published online: 26 May 2015 p541 | doi:10.1038/nrclinonc.2015.99 Hormone-receptor-positive breast cancer accounts for the majority of all breast cancers. The evolution of this disease from early stage to the metastatic setting leads to increased heterogeneity and the development of treatment resistance representing a great challenge for management decisions. In this Review, we examine the current evidence that can guide treatment decisions in patients with advanced-stage ER+ breast cancer, discuss how to tackle these therapeutic challenges and provide suggestions for the optimal management of this patient population. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Integrating biomarkers in colorectal cancer trials in the West and China Sabine Tejpar, Lin Shen, Xicheng Wang & Richard L. Schilsky Published online: 12 May 2015 p553 | doi:10.1038/nrclinonc.2015.88 Predictive biomarkers are invaluable for successful and cost-effective treatment of cancer, however, biomarker discovery is difficult and requires multiple independent studies to identify suitable predictors of efficacy. Clinical trials performed in the USA, Europe or Asia can offer unique opportunities for biomarker discovery and validation. In this Perspectives, the authors describe the current fragmented approach to biomarker discovery and validation, highlighting how collaborative engagement of the academic, regulatory and pharmaceutical communities can help address these issues. Abstract | Full Text | PDF
Advertisement
Call for Cover Images Wanted - an eye-catching image per journal to feature on the covers of the 2016 issues of the clinical Nature Reviews titles. We are offering the opportunity for one person's image to appear on the cover for 2016! Find out more
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.